Pharmaceutical - Respiratory and Pulmonary, Global

Filter

Popular Filters

GSK COPD survey shows many sufferers underestimate the severity of their condition

GSK COPD survey shows many sufferers underestimate the severity of their condition

12-11-2014

UK pharma major GlaxoSmithKline has conducted a global survey of people living with chronic obstructive…

GlobalGSKPharmaceuticalResearchRespiratory and PulmonaryUnited States

Asthma’s treatment pipeline very strong as more personalized medicines emerge

Asthma’s treatment pipeline very strong as more personalized medicines emerge

26-09-2014

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in…

AstraZenecabenralizumabBosatriaCinquilGlaxoSmithKlineGlobalPharmaceuticalResearchRespiratory and PulmonaryTeva Pharmaceutical Industries

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

14-08-2014

China-based ZAI Lab has obtained global rights for two novel compounds from French pharma major Sanofi,…

Chronic lower respiratory diseasesGlobalLicensingPharmaceuticalRespiratory and PulmonarySanofiZAI Lab

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Medivir licenses RSV program from Boehringer Ingelheim

Medivir licenses RSV program from Boehringer Ingelheim

05-08-2014

Swedish drugmaker Medivir has entered a license agreement with German family-owned pharma major Boehringer…

Boehringer IngelheimGlobalHuman respiratory syncytial virusLicensingMedivirMononegaviralesPharmaceuticalRespiratory and PulmonaryViral diseases

Global asthma treatment market to reach $21.6 billion by 2019

09-10-2013

The global asthma treatment market is estimated to reach a value of $21.6 billion by 2019, due not only…

GlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Galapagos and AbbVie enter into cystic fibrosis alliance

Galapagos and AbbVie enter into cystic fibrosis alliance

24-09-2013

Belgium-based Galapagos and US drugmaker AbbVie have entered into a global alliance to discover novel…

GlobalPharmaceuticalResearchRespiratory and Pulmonary

Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022

29-08-2013

The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of…

AdvairAnoroBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and PulmonarySpirivaTheravance

Global asthma market to reach 159 million lifetime cases by 2022

16-06-2013

Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion.…

GlaxoSmithKlineGlobalMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySeretideSingulair

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Global asthma and COPD drug market to reach nearly $27 billion in 2017

19-06-2012

The global asthma and chronic obstructive pulmonary disease (COPD) market was worth $25.102 billion in…

GlobalMarkets & MarketingPharmaceuticalRespiratory and Pulmonary

COMPANY SPOTLIGHT

Menarini

Back to top